TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03047798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthrinse
Description: A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen.
Study: NCT00752921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: 120 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04503863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22
Description: Single administration of middle dose NPC-22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22
Description: Single administration of high dose NPC-22

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-22 Placebo
Description: Single administration of NPC-22 Placebo
Study: NCT04005807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN-14967
Description: BPN-14967 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN-14967
Description: BPN-14967 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN-14967
Description: BPN-14967 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN-14967
Description: BPN-14967 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN-14967
Description: BPN-14967 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsules
Study: NCT03819270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372689
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT04173039

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum anti-CarP antibodies detection
Description: Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
Study: NCT02924727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan)
Description: LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
Study: NCT01084343

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MYM-V101
Description: * Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~* Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MYM-V101
Description: * Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~* Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks.
Study: NCT02453750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypersaline
Description: Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls \>10%, the previous step will be repeated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilator Response
Description: A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
Study: NCT02924727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696
Description: Matching placebo of LCZ696 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of ramipril
Description: Matching placebo of ramipril capsule
Study: NCT05953675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol 70%
Description: Once a week, the catheter will be closed with 3 mL ethanol 70% lock-solution after a completed hemodialysis. The fluid will stay in the catheter until next hemodialysis (ca. 48 hours). The fluid will be aspirated before the hemodialysis. Standard lock-solution of isotonic saline with heparin will be used for the remaining two hemodialysis procedures of the week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline with heparin
Description: Standard procedure of isotonic saline used as lock-fluid after completed hemodialysis.
Study: NCT00961831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 (BAY85-8050)
Description: Cancer patients, injection of BAY 85-8050, PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 (BAY85-8050)
Description: Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
Study: NCT05456334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser
Description: Comparance of pulsed-dye laser-mediated and conventional photodynamic therapy in a split-head design

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2-laser
Description: Comparance of fractional CO2-laser-mediated or plain daylight photodynamic therapy in a split-head design
Study: NCT02924727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of valsartan
Description: matching placebo of valsartan for one day to patients who will be randomized to received ramipril
Study: NCT00863395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Lidocaine 1% c Epinephrine for local anesthesia
Study: NCT02860221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: IV and topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: IV and topical administration
Study: NCT05456334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix cream
Description: Metvix-cream was used for photodynamic therapy in all experimental arms
Study: NCT02860221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: IV and topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study: NCT03163524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Coupon Text Modification and Reminders
Description: The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: e-Coupon standard text
Description: Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
Study: NCT04202809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is given earlier as registered, during chemotherapy and radiotherapy in treatment Arm A
Study: NCT01910974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic sub-mucosal dissection
Description: endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
Study: NCT02433262

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WHO (World Health Organisation)
Description: Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IADPSG
Description: Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
Study: NCT02143635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Study: NCT05456334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metvix cream
Description: Metvix-cream was used for photodynamic therapy in all experimental arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metvix cream
Description: Metvix-cream was used for photodynamic therapy in all experimental arms
Study: NCT02143635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ancillary treatment
Study: NCT02623348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pedometer
Description: pedometer-based physical activity recommendations
Study: NCT04809935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 98% dehydrated alcohol
Description: * coeliac plexus is identified and punctured~* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19G EUSRA needle, Taewoong Medical, Korea
Description: * 10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~* Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan
Study: NCT03659097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontally accelerated osteogenic orthodontics
Description: Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
Study: NCT06367491

Intervention type: OTHER
Intervention: Registration in a database
Description: All patients with bone metastasis enrolled at the centre will be entered into the database and followed until death or interruption of follow-up for any another cause
Study: NCT01662349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOE Antimicrobial Plasma Treatment System
Description: Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
Study: NCT01527084

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical intervention after percutaneous catheter drainage
Description: Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical intervention after percutaneous catheter drainage
Description: Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
Study: NCT01406392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 25mcg
Description: Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Misoprostol
Description: Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
Study: NCT03974932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: Dual-acting local anesthetic. Dose 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: Dual-acting local anesthetic. Dose 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: Dual-acting local anesthetic. Dose 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID.
Study: NCT00604955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin sulfate
Description: Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
Study: NCT00989469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib) and irinotecan (Campto)
Description: Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
Study: NCT01571557

Intervention type: DRUG
Intervention: dexamethasone 700 ug intravitreal implant
Description: dexamethasone 700 ug intravitreal implant administered according to standard of care.
Study: NCT03974932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID.
Study: NCT03310411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Administered orally
Study: NCT02285517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified Meek skin grafting technique
Description: patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
Study: NCT03310411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Lasmiditan
Description: Administered orally
Study: NCT02285517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesh skin grafting technique
Description: patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
Study: NCT03310411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sumatriptan
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Sumatriptan
Description: Administered orally
Study: NCT03483376

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prophylaxis
Description: Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental prophylaxis
Description: Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Description: Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.
Study: NCT04059471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Institut Pasteur
Description: Full dose and 500IU/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Institut Pasteur
Description: Full dose and 500IU/dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine, Institut Pasteur
Description: Full dose and 500IU/dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine, Institut Pasteur
Description: Full dose and 500IU/dose
Study: NCT03954990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: 4 tablets (2 g of metronidazole)
Study: NCT02796937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP
Description: Alpha-1 MP 60 mg/kg/week for up to 104 weeks
Study: NCT04223531

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
Study: NCT01520532

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
Study: NCT00548093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: PF-00299804 orally at 45 mg daily, on continuous schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: PF-00299804 orally at 45 mg daily, on continuous schedule
Study: NCT00986063

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic test for NVP induced rash
Description: The genotype statuses that capable of predict the cutaneous side effects from nevirapine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3TC/D4T/NVP or 3TC/AZT/NVP
Description: Standard HAART for AIDS patients in Thailand
Study: NCT01208220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: NPWT changed 3 times weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Ointment
Description: Apply TIW
Study: NCT02693093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-03

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-03

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-03

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03168971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Anxiety from Cancer (MAC)
Description: The intervention consists of seven telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques, problem-solving strategies, and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
Study: NCT03888950

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET-CT
Description: FDG PET/CT for oncological imaging of adult patients
Study: NCT00813527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and fenofibrate
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
Study: NCT03409393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The COPUS intervention
Description: The COPUS intervention consists of 8 weeks of High-Intensity Functional Training (HIFT). The frequency of the training is 3 sessions per week and the duration is one hour per session. The intervention is group-based and supervised. Each training session includes warm-up (15 min), followed by 30 minutes of HIFT based on a range of varied functional exercises, including elements of strength training and aerobic exercise. The sessions are supervised by a trained physiotherapist and exercise physiologist supported by 2 two trained bachelor students in Sports Science.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (OPUS treatment)
Description: Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (OPUS treatment)
Description: Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.